TG Therapeutics (NASDAQ:TGTX) Hits New 52-Week High – Time to Buy?

Posted by Geri Gentry on Nov 10th, 2026

TG Therapeutics, Inc. (NASDAQ:TGTX – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Tuesday. The stock traded as high as $65.35 and last traded at $65.8960, with a volume of 259,927 shares changing hands. The stock had previously closed at $63.38.

More TG Therapeutics News

Here are the key news stories impacting TG Therapeutics this week:

Positive Sentiment: Third-quarter revenue was $259.9 million, up 60.8% year over year and above analyst expectations of about $245.5 million. The company also reported EPS of $0.35; that was below the $0.37 consensus cited in some market data, though above the $0.28 Zacks estimate. TG Therapeutics reports third-quarter results and raises guidance
Positive Sentiment: TG Therapeutics raised its 2026 revenue guidance to $1 billion, above the roughly $961 million analyst consensus. CEO Michael Weiss also said global revenue could exceed $1 billion, reinforcing expectations for continued BRIUMVI sales growth. TG Therapeutics targets $1 billion in 2026 global revenue
Positive Sentiment: The company plans simplified intravenous dosing in mid-2027 and a subcutaneous launch in 2028. These longer-term formulation changes could make treatment more convenient, though their commercial impact is still ahead. TG Therapeutics dosing and launch plans
Negative Sentiment: EPS of $0.35 fell short of the $0.37 consensus estimate cited in the supplied market data, tempering the otherwise strong revenue report. TG Therapeutics third-quarter earnings report

Analyst Upgrades and Downgrades

TGTX has been the subject of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $78.00 target price on shares of TG Therapeutics in a research report on Tuesday, September 1st. B. Riley Financial upped their price target on TG Therapeutics from $55.00 to $86.00 and gave the company a “buy” rating in a research report on Monday, July 27th. JPMorgan Chase & Co. increased their price objective on TG Therapeutics from $65.00 to $72.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Weiss Ratings upgraded TG Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, November 4th. Finally, Zacks Research raised TG Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, TG Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $63.00.

View Our Latest Research Report on TG Therapeutics

TG Therapeutics Trading Up 2.9%

The company has a current ratio of 4.27, a quick ratio of 3.72 and a debt-to-equity ratio of 1.23. The company has a market cap of $9.98 billion, a PE ratio of 23.82, a P/E/G ratio of 2.60 and a beta of 1.89. The business’s 50-day simple moving average is $55.99 and its 200-day simple moving average is $44.66.

TG Therapeutics (NASDAQ:TGTX – Get Free Report) last posted its quarterly earnings results on Monday, November 9th. The biopharmaceutical company reported $0.35 EPS for the quarter, missing the consensus estimate of $0.37 by ($0.02). TG Therapeutics had a net margin of 55.22% and a return on equity of 73.49%. The company had revenue of $259.94 million for the quarter, compared to analysts’ expectations of $245.47 million. During the same quarter in the prior year, the firm earned $2.43 earnings per share. The company’s revenue was up 60.8% on a year-over-year basis. As a group, analysts expect that TG Therapeutics, Inc. will post 0.92 EPS for the current fiscal year.

Insider Buying and Selling

In other TG Therapeutics news, Director Laurence Charney sold 5,000 shares of the business’s stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $54.96, for a total value of $274,800.00. Following the transaction, the director owned 168,640 shares in the company, valued at $9,268,454.40. The trade was a 2.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 8.87% of the stock is owned by company insiders.

Institutional Investors Weigh In On TG Therapeutics

Institutional investors have recently made changes to their positions in the company. Stronghold Wealth Management L.L.C. lifted its stake in shares of TG Therapeutics by 6.3% in the third quarter. Stronghold Wealth Management L.L.C. now owns 3,922 shares of the biopharmaceutical company’s stock valued at $219,000 after buying an additional 231 shares during the period. Farther Finance Advisors LLC grew its position in TG Therapeutics by 45.8% during the third quarter. Farther Finance Advisors LLC now owns 993 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 312 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in TG Therapeutics by 51.9% during the first quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 365 shares during the period. Choreo LLC increased its stake in TG Therapeutics by 3.7% during the third quarter. Choreo LLC now owns 10,811 shares of the biopharmaceutical company’s stock valued at $603,000 after acquiring an additional 384 shares during the period. Finally, Chiron Capital Management LLC increased its stake in TG Therapeutics by 10.5% during the third quarter. Chiron Capital Management LLC now owns 4,200 shares of the biopharmaceutical company’s stock valued at $234,000 after acquiring an additional 400 shares during the period. 58.58% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Company Profile

(Get Free Report)

TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases, including autoimmune disorders and blood cancers. Its research has centered on therapies that target B cells, a type of immune cell involved in these conditions.

The company’s marketed product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved in the United States to treat adults with relapsing forms of multiple sclerosis. TG Therapeutics also has investigated other drug candidates and combinations for immune-related and hematologic diseases.

Headquartered in New York, TG Therapeutics serves patients in the United States and has expanded BRIUMVI’s availability into international markets, including Europe.